Can Fite Biopharma to file patent applications after promising cancer drug data, shares rise

Can Fite Biopharma

29/12/2021 13:00

** U.S.-listed shares of Israeli biotech co  CANF.N  up ~23%
at $1.55 premarket 
    ** Among top pct gainers across U.S. exchanges
    ** Co to file new patent applications in several countries
for treatment of all advanced solid tumors based on new positive
clinical data of co's drug candidate, Namodenoson  urn:newsml:reuters.com:*:nBw92r0Xsa
    ** Data shows patient with advanced hepatocellular carcinoma
(HCC) was cleared of all tumor lesions following treatment with
Namodenoson 
    ** HCC is most common type of liver cancer
    ** CANF expects to start patient enrollment for late-stage
study for Namodenoson for treating HCC patients with type of
cirrhosis or liver scarring in Q1 2022
    ** Up to Tuesday's close, stock had fallen 29.21% YTD 

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))